Keyphrases
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
100%
Disease Progression
46%
Tolvaptan
36%
Vasopressin V2 Receptor Antagonist
35%
Urine Volume
28%
V2 Receptor Antagonist
26%
Salt Intake
21%
Aquaretic
18%
Polyuria
17%
Protein Intake
17%
Copeptin
17%
Confidence Interval
17%
Vasopressin
16%
Disease Severity
15%
Cyst
15%
24-hour Urine Collection
15%
Older Adults
14%
Dapagliflozin
14%
Type 2 Diabetic Patients
14%
Renin-angiotensin System Inhibitors
14%
Thiazide Diuretics
14%
Volume Status
14%
Thiazides
14%
Estimated Glomerular Filtration Rate
14%
Prostaglandin E2
14%
Low Salt
14%
Osmoregulation
14%
Salt Effect
14%
Glucagon
14%
Observational Cohort Study
14%
Kidney
14%
Urine Production
10%
Polycystic Kidney Disease
10%
Low Protein
9%
Kidney Function Decline
8%
Renin
8%
Estimated Glomerular Filtration Rate Decline
8%
Lithium
8%
Treatment Options
8%
Placebo
8%
Kidney Failure
7%
Hazard Ratio
7%
Total Kidney Volume
6%
Tolerability
5%
Decline in Kidney Function
5%
Sodium Reabsorption
5%
Aldosterone
5%
Diuretic Effect
5%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
5%
Kidney Injury
5%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Polycystic Disease
80%
Tolvaptan
72%
Vasopressin V2 Receptor
58%
Receptor Antagonist
55%
Hydrochlorothiazide
40%
Side Effect
25%
Polyuria
22%
Placebo
21%
Amiloride Plus Hydrochlorothiazide
20%
Metformin
17%
Randomized Controlled Trial
17%
Tolerability
16%
Thiazide Diuretic Agent
14%
Dapagliflozin
14%
Renin-Angiotensin System Inhibitor
14%
Non Insulin Dependent Diabetes Mellitus
14%
Vasopressin
12%
Kidney Injury
8%
Disease Exacerbation
8%
Sodium Chloride
7%
Mouse
6%
Kidney Failure
6%
Sodium Glucose Cotransporter 2 Inhibitor
5%
Diuretic Agent
5%
Renin
5%
Clinical Trial
5%
Medicine and Dentistry
Polycystic Kidney Disease
85%
Receptor Antagonist
47%
Vasopressin V2 Receptor
47%
Disease Exacerbation
33%
Salt Intake
33%
Tolvaptan
33%
Protein Intake
32%
Sodium Chloride
28%
Polyuria
19%
Glycon
17%
Hydrochlorothiazide
17%
Kidney Function
17%
Glomerular Filtration Rate
17%
Side Effect
17%
Vasopressin
17%
Copeptin
15%
Disease Severity
14%
Cohort Study
14%
Renal Protection
14%
Glucagon
14%
Amiloride Plus Hydrochlorothiazide
14%